Literature DB >> 21037079

Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.

Tania Slatter1, Jennifer Gifford-Garner, Anna Wiles, Xin Tan, Yu-Jen Chen, Martin MacFarlane, Michael Sullivan, Janice Royds, Noelyn Hung.   

Abstract

Telomere maintenance by either telomerase activity or the recombination-mediated alternative lengthening of telomeres (ALT) mechanism is a hallmark of cancer. Tumors that use ALT as their telomere maintenance mechanism are characterized by long telomeres of great heterogeneity in length and by specific nuclear structures of co-localized promyelocytic leukemia protein and telomere DNA, called ALT-associated promyelocytic leukemia bodies (APBs). Recent advances have revealed a direct role for APBs in telomere recombination in ALT-positive cells. In this study, we investigated the possibility that APBs could occur before the long 'alternatively' lengthened telomeres arise, particularly in low-grade tumors. We measured APBs, telomere length, and telomerase activity in 64 astrocytomas inclusive of grade 1-4 tumors. Almost all grade 1-3 tumors (93%) were APB-positive using published criteria. Grade 2-3 APB-positive tumors also had long telomeres and were confirmed as ALT positive. However, grade 1 tumors lacked long telomeres and were therefore classified as ALT negative, but positive for telomere-associated promyelocytic leukemia bodies (TPB). This is the first report of a TPB-positive but ALT-negative tumor, and suggests that low-grade tumors have the foundation for recombinational telomere repair, as in ALT. Further work is warranted to characterize the TPB-positive phenotype in other early malignancies, as well as to determine whether TPBs predispose to telomere maintenance by ALT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21037079      PMCID: PMC2993310          DOI: 10.2353/ajpath.2010.100468

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.

Authors:  Kerrie L McDonald; Julie McDonnell; Alessandra Muntoni; Jeremy D Henson; Monika E Hegi; Andreas von Deimling; Helen R Wheeler; Ray J Cook; Michael T Biggs; Nicholas S Little; Bruce G Robinson; Roger R Reddel; Janice A Royds
Journal:  J Neuropathol Exp Neurol       Date:  2010-07       Impact factor: 3.685

2.  Extension of life-span by introduction of telomerase into normal human cells.

Authors:  A G Bodnar; M Ouellette; M Frolkis; S E Holt; C P Chiu; G B Morin; C B Harley; J W Shay; S Lichtsteiner; W E Wright
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

3.  The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit.

Authors:  T M Bryan; L Marusic; S Bacchetti; M Namba; R R Reddel
Journal:  Hum Mol Genet       Date:  1997-06       Impact factor: 6.150

Review 4.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

Review 5.  Telomere dynamics and telomerase activity in in vitro immortalised human cells.

Authors:  T M Bryan; R R Reddel
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

6.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines.

Authors:  T M Bryan; A Englezou; L Dalla-Pozza; M A Dunham; R R Reddel
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

7.  Telomerase activity in reactive and neoplastic lymphoid tissues: infrequent detection of activity in Hodgkin's disease.

Authors:  P Brousset; T al Saati; N Chaouche; R C Zenou; D Schlaifer; S Chittal; G Delsol
Journal:  Blood       Date:  1997-01-01       Impact factor: 22.113

Review 8.  Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature.

Authors:  C M Dirven; J J Mooij; W M Molenaar
Journal:  Childs Nerv Syst       Date:  1997-01       Impact factor: 1.475

9.  Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span.

Authors:  H Vaziri; S Benchimol
Journal:  Curr Biol       Date:  1998-02-26       Impact factor: 10.834

10.  Telomere elongation in immortal human cells without detectable telomerase activity.

Authors:  T M Bryan; A Englezou; J Gupta; S Bacchetti; R R Reddel
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

View more
  15 in total

1.  Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

Authors:  Christopher M Heaphy; Andrea P Subhawong; Seung-Mo Hong; Michael G Goggins; Elizabeth A Montgomery; Edward Gabrielson; George J Netto; Jonathan I Epstein; Tamara L Lotan; William H Westra; Ie-Ming Shih; Christine A Iacobuzio-Donahue; Anirban Maitra; Qing K Li; Charles G Eberhart; Janis M Taube; Dinesh Rakheja; Robert J Kurman; T C Wu; Richard B Roden; Pedram Argani; Angelo M De Marzo; Luigi Terracciano; Michael Torbenson; Alan K Meeker
Journal:  Am J Pathol       Date:  2011-09-01       Impact factor: 4.307

2.  Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade.

Authors:  Sandra Sampl; Sibylle Pramhas; Christian Stern; Matthias Preusser; Christine Marosi; Klaus Holzmann
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

Review 3.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

Review 4.  Pathological and molecular advances in pediatric low-grade astrocytoma.

Authors:  Fausto J Rodriguez; Kah Suan Lim; Daniel Bowers; Charles G Eberhart
Journal:  Annu Rev Pathol       Date:  2012-10-29       Impact factor: 23.472

5.  Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma.

Authors:  Noelyn A Hung; Ramona A Eiholzer; Stenar Kirs; Jean Zhou; Kirsten Ward-Hartstonge; Anna K Wiles; Chris M Frampton; Ahmad Taha; Janice A Royds; Tania L Slatter
Journal:  Mod Pathol       Date:  2016-01-15       Impact factor: 7.842

6.  HP1-mediated formation of alternative lengthening of telomeres-associated PML bodies requires HIRA but not ASF1a.

Authors:  Wei-Qin Jiang; Akira Nguyen; Ying Cao; Andy C-M Chang; Roger R Reddel
Journal:  PLoS One       Date:  2011-02-15       Impact factor: 3.240

7.  The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.

Authors:  Janice A Royds; Shafagh Al Nadaf; Anna K Wiles; Yu-Jen Chen; Antonio Ahn; Alisha Shaw; Sara Bowie; Frederic Lam; Bruce C Baguley; Antony W Braithwaite; Martin R MacFarlane; Noelyn A Hung; Tania L Slatter
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

8.  Telomerase-independent paths to immortality in predictable cancer subtypes.

Authors:  Stephen T Durant
Journal:  J Cancer       Date:  2012-01-31       Impact factor: 4.207

9.  Increased paired box transcription factor 8 has a survival function in glioma.

Authors:  Noelyn Hung; Yu-Jen Chen; Ahmad Taha; Magnus Olivecrona; Ronald Boet; Anna Wiles; Tracy Warr; Alisha Shaw; Ramona Eiholzer; Bruce C Baguley; Michael R Eccles; Antony W Braithwaite; Martin Macfarlane; Janice A Royds; Tania Slatter
Journal:  BMC Cancer       Date:  2014-03-06       Impact factor: 4.430

Review 10.  PML body meets telomere: the beginning of an ALTernate ending?

Authors:  Inn Chung; Sarah Osterwald; Katharina I Deeg; Karsten Rippe
Journal:  Nucleus       Date:  2012-05-01       Impact factor: 4.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.